Pembrolizumab Lenvatinib Uveal Melanoma Efficacy
summary of the PLUME Trial Findings on Pembrolizumab and Lenvatinib for Uveal Melanoma
This article details the results of the phase 2 PLUME trial (NCT05282901) investigating the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) in patients with uveal melanoma. Here’s a breakdown of the key findings:
Key Results:
* Promising PFS: the combination showed promising progression-free survival (PFS) rates in both HLA-A02:01-negative and -positive patient groups.
* HLA-A02:01-negative, tebentafusp-naive: 31.8% PFS rate at 27 weeks (95% CI, 13.9%-54.9%)
* HLA-A*02:01-positive,pretreated with tebentafusp: 60.7% PFS rate at 27 weeks (95% CI, 40.6%-78.5%)
* Potential Synergy: The combination appeared notably effective in patients previously treated with tebentafusp, suggesting a potential synergistic effect.
* Manageable Safety Profile: The safety profile was consistent with previous trials of pembrolizumab and lenvatinib, with no treatment-related deaths. Dose holds and reductions were common, particularly with lenvatinib.
* Common Adverse Events: the most frequent treatment-related adverse events included fatigue, hypertension, diarrhea, hypothyroidism, arthralgia, cytolytic hepatitis, mucositis, dysphonia, and abdominal pain.
Study Design:
* PLUME Trial: A single-arm, phase 2 trial conducted at the Institut Curie in Paris, france.
* Participants: 51 patients with uveal melanoma.
Critically important Considerations:
* Small sample Size & Single-Arm Design: The researchers cautioned that the results should be interpreted cautiously due to the limited sample size and the study’s single-arm design.
* Ongoing Research: Biomarker analyses and real-world comparisons are underway to further refine patient selection and understanding of the treatment’s efficacy.
In essence, the PLUME trial suggests that the combination of pembrolizumab and lenvatinib is a promising treatment option for uveal melanoma, particularly for patients who have previously received tebentafusp. Though, further research is needed to confirm these findings and optimize treatment strategies.